After years of wide-open compounding, regulators say they’re ready to enforce limits and restore control over the ...

“In the past, if I had lost weight, I got a self-esteem boost, which is almost like dopamine. It makes you crave sex more,” ...

It’s estimated that about one in 10 Americans have taken a GLP‑1 weight‑loss drug, and demand is surging. Ads are everywhere, but so are concerns about safety, cost and ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

GLP-1 medications can be effective for weight loss and diabetes management but require lifestyle changes and can have severe ...

Empower Pharmacy could be banned from doing business in California after the state's pharmacy board moved to revoke Empower's probation in November, records show.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and ...

State health plan overseers voted Thursday to eliminate coverage for GLP-1 drugs for obesity, capping off months of torn decision-making over how to tamp down surging health care costs while ...

Whether it's about promoting protein or smaller portions, the restaurant industry is preparing for a shift in consumer ...

David Graziano, head of retail network at GoodRx, says the FDA’s crackdown on non-approved or “copycat” GLP-1 drugs could shift demand toward FDA-approved therapies while increasing the importance of ...